MA32455B1 - Oxazolopyrimidines en tant qu'agonistes des récepteurs edg-1 - Google Patents

Oxazolopyrimidines en tant qu'agonistes des récepteurs edg-1

Info

Publication number
MA32455B1
MA32455B1 MA33493A MA33493A MA32455B1 MA 32455 B1 MA32455 B1 MA 32455B1 MA 33493 A MA33493 A MA 33493A MA 33493 A MA33493 A MA 33493A MA 32455 B1 MA32455 B1 MA 32455B1
Authority
MA
Morocco
Prior art keywords
edg
formula
compounds represented
oxazolopyrimidines
receptor agonists
Prior art date
Application number
MA33493A
Other languages
Arabic (ar)
English (en)
Inventor
Dieter Kadereit
Matthias Schaefer
Werngard Czechtizky
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MA32455B1 publication Critical patent/MA32455B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention porte sur des composés oxazolopyrimidines représentés par la formule i dans laquelle a, r1, r2 et r3 sont définis comme indiqué dans les revendications. Les composés représentés par la formule i modulent l'activité du récepteur edg-1 et en particulier sont des agonistes de ce récepteur et sont utiles pour le traitement de maladies telles que l'athérosclérose, l'insuffisance cardiaque ou une maladie oblitérante artérielle périphérique, par exemple. L'invention porte en outre sur des procédés pour la fabrication de composés représentés par la formule i, sur leur utilisation, en particulier comme ingrédients actifs dans des produits pharmaceutiques, et sur des compositions pharmaceutiques les comprenant.
MA33493A 2008-07-15 2011-01-05 Oxazolopyrimidines en tant qu'agonistes des récepteurs edg-1 MA32455B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08290694 2008-07-15
PCT/EP2009/004770 WO2010006704A1 (fr) 2008-07-15 2009-07-02 Oxazolopyrimidines comme agonistes du récepteur edg-1

Publications (1)

Publication Number Publication Date
MA32455B1 true MA32455B1 (fr) 2011-07-03

Family

ID=39967817

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33493A MA32455B1 (fr) 2008-07-15 2011-01-05 Oxazolopyrimidines en tant qu'agonistes des récepteurs edg-1

Country Status (20)

Country Link
US (1) US8735387B2 (fr)
EP (2) EP2583720A1 (fr)
JP (1) JP5449346B2 (fr)
KR (1) KR20110042286A (fr)
CN (1) CN102159582B (fr)
AR (1) AR072496A1 (fr)
AU (1) AU2009270511B2 (fr)
BR (1) BRPI0915781A2 (fr)
CA (1) CA2730843A1 (fr)
CL (1) CL2011000071A1 (fr)
CO (1) CO6331436A2 (fr)
IL (1) IL210639A0 (fr)
MA (1) MA32455B1 (fr)
MX (1) MX2011000211A (fr)
NZ (1) NZ590377A (fr)
RU (1) RU2503680C2 (fr)
TW (1) TW201016707A (fr)
UY (1) UY31981A (fr)
WO (1) WO2010006704A1 (fr)
ZA (1) ZA201008786B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI485153B (zh) 2010-01-13 2015-05-21 Sanofi Aventis ２，５，７－經取代唑并嘧啶衍生物
TWI478929B (zh) 2010-01-13 2015-04-01 Sanofi Aventis 含２，５，７－經取代唑并嘧啶環之羧酸衍生物
MX2012007837A (es) 2010-01-14 2012-07-30 Sanofi Sa Derivados de oxazolopirimidina 2, 5 - sustituidos.
JP5841068B2 (ja) * 2010-01-14 2016-01-06 サノフイ ２，５−置換されたオキサゾロピリミジン環を有する複素環式カルボン酸誘導体
PT2523962E (pt) * 2010-01-14 2014-02-06 Sanofi Sa Derivados de ácidos carboxílicos com um anel oxazolopirimidina substituído em 2,5
AU2011225122B8 (en) 2010-03-12 2013-12-12 Nippon Soda Co., Ltd. Compound containing pyridine ring and method for producing halogenated picoline derivative and tetrazolyloxime derivative
US8580816B2 (en) * 2011-07-07 2013-11-12 Sanofi Carboxylic acid derivatives having an oxazolo[5,4-b]pyridine ring
US8907093B2 (en) * 2011-07-07 2014-12-09 Sanofi Carboxylic acid derivatives having an oxazolo[4,5-c]pyridine ring
US9321787B2 (en) * 2011-07-07 2016-04-26 Sanofi Carboxylic acid derivatives having an oxazolo[5,4-d]pyrimidine ring
US8735402B2 (en) * 2011-07-07 2014-05-27 Sanofi Cycloalkyloxycarboxylic acid derivatives
SI2841437T1 (sl) 2012-04-26 2017-09-29 Bristol-Myers Squibb Company Derivati imidazotiadiazola in imidazopirazina kot proteazno aktivirani receptor 4 (PAR4) inhibitorji za zdravljenje agregacije trombocitov
SG11201406759YA (en) * 2012-04-26 2014-11-27 Bristol Myers Squibb Co Imidazothiadiazole derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation
US10577308B2 (en) 2015-03-26 2020-03-03 The Florey Institute Sodium channel modulators
WO2022224267A1 (fr) * 2021-04-21 2022-10-27 Natco Pharma Limited Procédé amélioré pour la préparation de dérivés de 7-(morpholinyl)-2-(n-pipérazinyl)méthylthiéno[2, 3-c]pyridine

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3679682A (en) * 1970-04-23 1972-07-25 Fmc Corp CERTAIN 5H-ISOXAZOLO{8 5,4-d{9 PYRIMIDIN-4-ONES
DK1390371T3 (da) * 2001-05-14 2006-06-19 Novartis Ag Oxazolo- og furopyrimidiner samt deres anvendelse i lægemidler mod tumorer
WO2003061567A2 (fr) 2002-01-18 2003-07-31 Merck & Co., Inc. Antagonistes sélectifs du récepteur s1p1/edg1
JP2006524672A (ja) 2003-04-25 2006-11-02 ユニバーシティー・カッレッジ・カーディフ・コンサルタンツ・リミテッド ウイルス感染の治療において使用するための複素環式化合物
MXPA05011597A (es) * 2003-04-30 2005-12-15 Novartis Ag Derivados de aminopropanol como moduladores del receptor 1-fosfato de esfingosina.
CL2004001120A1 (es) * 2003-05-19 2005-04-15 Irm Llc Compuestos derivados de amina sustituidas con heterociclos, inmunosupresores; composicion farmaceutica; y uso para tratar enfermedades mediadas por interacciones de linfocito, tales como enfermedades autoinmunes, inflamatorias, infecciosas, cancer.
AU2004272437A1 (en) 2003-09-09 2005-03-24 Ono Pharmaceutical Co., Ltd. CRF antagonists and heterobicyclic compounds
EP1697333A4 (fr) 2003-12-17 2009-07-08 Merck & Co Inc Carboxylates propanoiques 3,4-disusbstitues utilises en tant qu'agonistes du recepteur s1p (edg)
US20050239806A1 (en) 2004-01-13 2005-10-27 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
WO2005123677A1 (fr) 2004-06-16 2005-12-29 Actelion Pharmaceuticals Ltd Utilisation de derives de 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa[a]pentalene a substitution 4-carbonyle comme agonistes du recepteur couple aux proteines g s1p1/edg1 et agents immunosuppresseurs
WO2006010379A1 (fr) 2004-07-29 2006-02-02 Actelion Pharmaceuticals Ltd. Nouveaux derives du thiophene utilises comme agents immunosupresseurs
CA2583681A1 (fr) 2004-10-22 2006-05-04 Merck & Co., Inc. Carboxylates, sulfonates, phosphonates, phosphinates 2-(aryl)azacyclylmethyle et heterocycles utilises comme agonistes des recepteurs s1p
EP1965807A4 (fr) * 2005-11-23 2010-10-27 Epix Delaware Inc Composes modulateurs du recepteur s1p et utilisation associee
EP1900729A1 (fr) * 2006-09-15 2008-03-19 Novartis AG Benzoxazoles et oxazolopyridines et leur utilisation comme inhibiteurs de Janus kinases

Also Published As

Publication number Publication date
ZA201008786B (en) 2012-01-25
US20110190490A1 (en) 2011-08-04
EP2318415B1 (fr) 2013-02-20
TW201016707A (en) 2010-05-01
CA2730843A1 (fr) 2010-01-21
KR20110042286A (ko) 2011-04-26
MX2011000211A (es) 2011-03-03
CN102159582B (zh) 2014-05-07
EP2318415A1 (fr) 2011-05-11
CN102159582A (zh) 2011-08-17
AU2009270511A1 (en) 2010-01-21
AR072496A1 (es) 2010-09-01
AU2009270511B2 (en) 2013-07-18
NZ590377A (en) 2011-11-25
JP2011527994A (ja) 2011-11-10
WO2010006704A1 (fr) 2010-01-21
BRPI0915781A2 (pt) 2015-11-10
JP5449346B2 (ja) 2014-03-19
RU2503680C2 (ru) 2014-01-10
UY31981A (es) 2010-02-26
RU2011105388A (ru) 2012-08-20
IL210639A0 (en) 2011-03-31
EP2583720A1 (fr) 2013-04-24
CO6331436A2 (es) 2011-10-20
US8735387B2 (en) 2014-05-27
CL2011000071A1 (es) 2011-05-06

Similar Documents

Publication Publication Date Title
MA32455B1 (fr) Oxazolopyrimidines en tant qu'agonistes des récepteurs edg-1
MX2015003653A (es) Derivados de amida del acido benzoimidazol-carboxilico como moduladores del receptor apj.
NO20074592L (no) Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister
EA201001733A1 (ru) Производные тиенопиридона в качестве активаторов амр-активированной протеинкиназы (амрк)
CY1115058T1 (el) Παραγωγα 1,2,3- τριαζολης για χρηση ως αναστολεις στεατοϋλο-coa δεσατουρασης
MX2010011047A (es) Derivados de tienopiridonas como activadores de proteina cinasa activada por amp (ampk).
CY1111170T1 (el) Ενωσεις διαρυλ αιθερα ουριας
UA113051C2 (xx) Гетероциклічні похідні та їх застосування у лікуванні неврологічних розладів
JO2870B1 (en) Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
PL2150530T3 (pl) Podstawione pochodne sulfonamidu
TN2010000125A1 (en) Substituted biphenyl gpr40 modulators
NO20085068L (no) Fenylamino-benzoksazolsubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
EA201391786A1 (ru) Галоген-алкил-1,3-оксазины в качестве ингибиторов bace1 и/или bace2
PH12013502262A1 (en) Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as bace1 and/or bace2 inhibitors
MX2013007558A (es) 1,4-oxazinas como inhibidores de los genes enzima de segmentacion de la proteina precursora del sitio 1 y/o 2 (bace1 y/o bace2).
CR20130264A (es) Compuestos pirimidinona para uso en el tratamiento de enfermedades o condiciones mediadas por lp-pla2
PH12013500644A1 (en) Co-crystals and salts of ccr3-inhibitors
MX2013014194A (es) 1,3-tiazepinas fusionadas a ciclopropilo como inhibidores de beta-secretasa 1 (bace) y/o beta-secretasa 2 (bace 2).
MA34094B1 (fr) Dérivés de 3-(hétéroarylamino)-1,2,3,4-tétrahydro-9h-carbazole et leur utilisation comme modulateurs du récepteur de la prostaglandine d2
TW200602330A (en) Compounds and compositions as PPAR modulators
EA201001586A1 (ru) Соединения и композиции в качестве ингибиторов itpkb
MA32061B1 (fr) Triazolopyridazines en tant qu'inhibiteurs de par1, production de celles-ci, et utilisation en tant que médicaments
PT2523960E (pt) Derivados heterocíclicos de ácidos carboxílicos com um anel oxazolopirimidina substituído em 2,5
MY148732A (en) Triazolium salts as par1 inhibitors, production thereof, and use as medicaments
NO20090067L (no) Farmasoytiske kombinasjoner for behandling av respiratoriske sykdommer